Sales of blood glucose test strips will drive the Polish IVD market
to grow at an annual rate of close to 10% between 2012 and 2016, according to a new market research report. PMR Publications says the Polish IVD market totaled €316 million ($403 million) in 2011, with sales of blood glucose test strips accounting for 44% of total IVD sales.
The Krakow-based research firm notes that the glucose strip segment expanded by nearly 20% in 2011. Government reimbursement policy and its effect on the diabetes product segment played a major role in this increase, according to PMR. A new list of reimbursable products introduced on January 1, 2012, did not include testing strips from manufacturers such as Roche and Abbott Laboratories. Fearing higher prices for blood glucose test strips, patients “bought diagnostic tests from pharmacies in massive quantities” as 2011 drew to a close, writes the report’s author, Agnieszka Skonieczna, senior pharmaceutical market analyst. The products were restored to the reimbursement list on March 1, 2012, she reports.
Underlying this growth is an increase in the incidence of diabetes in Poland, according to Skonieczna. The Polish Ministry of Health reports that 6.5% of the country’s population, or 2 million people, suffered from the disease in 2011. That number will double over the next 20 years.
In terms of value sales of reagents account for the largest portion of the market, making up 91% of overall IVD-related sales. The economic downturn caused healthcare facilities to reduce equipment purchases, but the facilities still needed these reagents to conduct their ongoing research, Skonieczna says.